Hyperlipidemia. Hyperlipidemia
Conditions
Interventions
Intervention 1: The intervention group completed 8 weeks of daily 2 g L - Carnitine (Company C, followed by Karen Canada) pill of 1000 mg Oral form. Intervention 2: and placebo groups completed 8 we
Treatment - Drugs
Placebo
The intervention group completed 8 weeks of daily 2 g L - Carnitine (Company C, followed by Karen Canada) pill of 1000 mg Oral form
and placebo groups completed 8 weeks 2g daily Oral form use.
Sponsors
Baqiyatallah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: risk of hyperlipidemia in the diagnosis and referral specialist measure cholesterol = 200 mg dL; triglycerides = 200 mg per deciliter;aged between 20 and 65 years; Gender (Female and Male) Exclusion criteria: hypothyroidism; Pregnancy & menopause;smoking;drugs and alcohol;inflammatory diseases; such as diabetes; cancer; chronic liver disease (Fatty Liver, Cirrhosis of the liver, hepatitis, etc.) and use of Anti-seizure drugs; anti-supplements oxidant.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lipid Profile ( Tg,Total Chol, LDL-C, HDL-C ). Timepoint: Baseline and the end of the eighth week. Method of measurement: Their past record of blood test with automated analyzers. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactshahin vahabi
Baqiyatallah University of Medical Sciences
Outcome results
None listed